Expression of Cycloxygenase-2 in Cervical Carcinoma and Its Correlation with Clinicopathological Variables by Divya, N
 EXPRESSION OF CYCLOXYGENASE -2 IN CERVICAL 
CARCINOMA AND ITS CORRELATION WITH 
CLINICOPATHOLOGICAL VARIABLES 
Dissertation submitted in  
partial fulfilment of the requirements for the degree of 
M.D. (PATHOLOGY) 
BRANCH - III 
 
GOSCHEN INSTITUTE OF PATHOLOGY AND ELECTRON 
MICROSCOPY 
MADRAS MEDICAL COLLEGE 
CHENNAI – 600 003 
 
 
 
 
 
 
THE TAMIL NADU 
DR. M.G.R. MEDICAL UNIVERSITY 
CHENNAI 
 
APRIL 2016 
 CERTIFICATE 
 This is to certify that this Dissertation entitled   “EXPRESSION OF 
CYCLOXYGENASE -2 IN CERVICAL CARCINOMA AND ITS 
CORRELATION WITH CLINICOPATHOLOGICAL VARIABLES” is the 
bonafide original work of Dr.DIVYA. N, in partial fulfillment of the 
requirement for M.D., (Branch III) in Pathology examination of the 
TamilnaduDr.M.G.R Medical University to be held in April 2016. 
 
 
 
Prof. Dr. GEETHA DEVADAS MD, D.C.P         Prof.Dr.M.SARASWATHY, M.D 
Professor Of Pathology,    Director & Professor 
Institute of Pathology,     Institute of Pathology , 
Madras Medical College,             Madras Medical College 
Chennai – 600003.                Chennai – 600003. 
 
 
 
  
Prof. Dr. R.VIMALA, M.D., 
Dean, 
Madras Medical College and  
Government General Hospital, 
Chennai - 600003 
  
DECLARATION 
          I, Dr.DIVYA.N, solemnly declare that the dissertation titled  
“EXPRESSION OF CYCLOXYGENASE-2 IN CERVICAL 
CARCINOMA AND ITS CORRELATION WITH 
CLINICOPATHOLOGICAL VARIABLES” is the bonafide work done by 
me at Department  of  Pathology, Institute of Obstetrics and  Gynecology, 
Egmore, Chennai under the expert guidance and supervision of  
Prof.Dr.GEETHA DEVADAS.M.D.D.C.P, Professor of Pathology, 
Institute of Pathology, Madras Medical College. The dissertation is submitted 
to the Tamil Nadu Dr. M.G.R Medical University towards partial fulfillment 
of requirement for the award of M.D., Degree (Branch III) in Pathology. 
 
 
 
Place:  Chennai 
Date:         Dr. DIVYA. N 
 
  
 ACKNOWLEDGEMENT 
 I express my sincere thanks to Prof. Dr.R.VIMALA, M.D., Dean, 
Madras Medical College and Government General Hospital, for permitting 
me to utilize the facilities of the Institution. 
 
 I take the opportunity to express my thanks to  
Prof. Dr.M.SARASWATHY, M.D., Director and Professor, Institute of 
Pathology, Madras Medical College, Chennai for herkeen interest, constant 
encouragement and valuable suggestions throughout the study. 
 
I am extremely thankful to Prof. Dr. GEETHA DEVADAS. 
M.D.D.C.P., Professor of Pathology, Institute of Pathology, Madras Medical 
College, Chennaifor her expert guidance, valuable suggestions, constant 
support, advice and encouragement throughout the study. 
 
I extend my sincere thanks to Prof.Dr.KanchanaM.D, Professor of 
Pathology, Institute of Obstetrics and Gynecology, Egmore, Chennai for her 
valuable suggestions, advice and encouragements throughout the study. I also 
thankthe Director and Professor of Institute of Obstetrics and Gynecology, 
Egmore, Chennai, for permitting me to utilize the materials of the Institution. 
 
 
I am truly thankful to Prof.Dr.Padmavathi M.D., Prof. Dr. 
SudhaVenkateshM.D.,Prof.Dr.Ramamoorthy M.D, Prof. Dr. K. Rama 
M.D., Prof.Dr.Rajavelu Indira M.D, Prof. Dr. S. Pappathi M.D., D.C.H., 
Prof. Dr. ShanthaRavisankar M.D., for their valuable suggestions and 
encouragement throughout the study. 
 
 I wouldlike to thank the Institutional Ethics Committee for approving 
my study.  
 
      On a personal level, I extent my gratitude to my parents Mr. U.V. 
Narayanankutty and Mrs. C.M Ambujam, daughter Rithu Ramesh and all the 
members of the  family, with a special mention to Deepthi N B.Sc M.B.A, for 
their love,friendship,advice and support in my personal and professional 
endeavors. 
 
          I sincerely acknowledge the cooperation of my husband Dr.Ramesh.B 
M.D, D.C.H who, as always, has patiently guided me at every stage, offering 
me helpful criticisms and suggestions. 
 
        I thank my Friends, Colleagues, Senior Postgraduates, Junior 
Postgraduates, Technicians and the Staffs for their continuing support and 
helpful advice 
  
   
   
  
ABBREVIATIONS 
SCC  : Squamous cell carcinoma 
ADC       : Adenocarcinoma 
EGFR  : Epidermal growth factor receptor 
WHO  : World Health Organisation 
IHC  : Immunohistochemistry 
HPV  : Human papillomavirus 
FIGO  :  International Federation of Gynecological  
   Oncologists 
COX  : Cycloxygenase 
CIN  : Cervical Intraepithelial Neoplasia 
VIA  : Visual Inspection with Acetic acid 
VILI  : Visual Inspection with Lugol’s Iodine 
LSIL  : Low grade squamous intraepithelial lesion 
HSIL  : High grade squamous intraepithelial lesion 
OCP  : Oral Contraceptive Pills 
CT  : Computerised Tomography 
MRI  : Magnetic Resonance Imaging 
VEGF  : Vascular Endothelial Growth Factor 
 
CONTENTS 
S. NO. TITLE PAGE NUMBER 
1 INTRODUCTION 1 
2 AIMS AND OBJECTIVES 3 
3 REVIEW OF LITERATURE 4 
4 MATERIALS AND METHODS 35 
5 OBSERVATION AND RESULTS 40 
6 DISCUSSION 66 
7 SUMMARY 74 
8 CONCLUSION 77 
 
ANNEXURES 
BIBLIOGRAPHY 
 
 MASTER CHART  
 
ABSTRACT 
Cervical carcinoma ranks fourth among the leading causes of cancer 
worldwide, after carcinoma of breast, colorectal carcinoma and lung carcinoma. In 
developing countries like India, cervical carcinoma accounts for the second most 
common cancer occurring in women and also the second leading cancer killer next 
only to carcinoma breast.There are many well established prognostic factors for 
carcinoma of cervix including FIGO stage, HPV status, age of the patient, tumor size, 
depth of stromal invasion, nodal status, parametrial involvement, lymphovascular 
invasion etc. Recently, several biomarkers were studied which may have a role in 
predicting the prognosis and also in the selection of therapeutic strategies that can be 
helpful to further improve patient survival for carcinoma of cervix. Of these one 
important molecular marker is cycloxygenase 2 (COX2). 
In our study, we evaluate thepattern of COX-2expression in cervical 
carcinomas and its association with various clinicopathological variables like age of 
the patient, stage, menstrual status, tumor size, parametrial involvement, vaginal 
involvement, nodal status and histological grade of tumor. 
 
AIMS AND OBJECTIVES 
To assess the expression of Cycloxygenase 2 (COX-2) in invasive cervical 
carcinomas. To compare the clinical behaviour of cervical carcinomas and 
cyclooxygenase 2 expression. To correlate the expression of cyclooxygenase -2 
(COX2) with various clinicopathological variables. To assess the value of COX2 as a 
prognostic and predictive marker. 
 
MATERIALS AND METHODS 
For the 50 patients included in the study,the  paraffin  tissue  blocks  were  cut  
and  stained with eosin and hematoxylin.Immunohistochemical analysis of marker 
COX2 was done in all these cases and the results compared with  the clinical and 
morphological parameters to study the efficiency of   marker (COX2). 
 
RESULTS 
When the menstrual status and stage of the disease were compared, it was 
noted that menstruating females presented in early stages of the disease, whereas 
postmenopausal females presented in advanced stages of disease. This correlation was 
statistically found to be significant with a p value of 0.004. 
In our study, it was noted that smaller tumors showed less COX2 expression 
whereas it was significantly higher for larger tumors. This was found to be statistically 
significant with a p value of 0.007. 
On comparing the COX2 expression with nodal status of the patients, it was 
noted that among cases with enlarged nodes, 44.2% had positive COX2 expression. 
This was found to be statistically significant with a p value of 0.026. 
On comparing COX2 expression with clinical stage of the disease, it was noted 
that COX2 expression was more in tumors of higher clinical stage. 
 
CONCLUSION 
In our study, expression of COX2 was found to be correlating with many of the 
established poor prognostic factors. Hence it can be concluded that this study is 
pointingtowards the possibility of considering COX2 as a poor prognostic marker for 
cervix carcinoma 
 
key words: COX2, FIGO, HPV, cervix carcinoma. 
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INTRODUCTION 
  
Cervical carcinoma ranks fourth among the leading causes of cancer 
worldwide, after carcinoma of breast, colorectal carcinoma and lung 
carcinoma. In developing countries like India, cervical carcinoma accounts for 
the second most common cancer occurring in women and also the second 
leading cancer killer next only to carcinoma breast. Every year 528,000 new 
cases of carcinoma cervix are diagnosed. Of this, one-fifth of cases occur in 
India[1]. The most important etiological factors responsible for the development 
of cervical carcinoma and its precursor lesions are chronic infection with HPV 
(human papilloma virus)[2]. Invasive carcinomas of cervix usually progress 
from dysplasias over a period of several years. Hence screening programmes, if 
started early, can identify most lesions in their initial stages, even before the 
development of overt malignancy.  
There are many well established prognostic factors for carcinoma of 
cervix including FIGO stage, HPV status, age of the patient, tumor size, depth 
of stromal invasion, nodal status,parametrial involvement,lymphovascular 
invasion etc. Recently, several biomarkers were studied which may have a role 
in predicting the prognosis and also in the selection of therapeutic strategies 
that can be helpful to further improve patient survival for carcinoma of cervix. 
Of these one important molecular marker is cycloxygenase 2 (COX2). 
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Cycloxygenase (COX) is a catalystic enzyme that aids in the formation 
of prostaglandin from arachidonic acid. Two distinct forms of COX exists – 
(1)COX-1, (2) COX-2. COX-1 is known as the housekeeping gene and have 
constant levels of expression in all cells. COX-2 is an immediate-early 
response gene that is activated by several factors liketumor promoter 
oncogenes, growth factors and carcinogens. It has been proven that COX-2 is 
overexpressed in malignant cells especially in colorectal neoplasms and 
carcinoma of cervix. 
In our study, we evaluate thepattern of COX-2expression in cervical 
carcinomas and its association with various clinicopathological variables like 
age of the patient, stage, menstrual status, tumor size, parametrial involvement, 
vaginal involvement, nodal status and histological grade of tumor. 
  
  
 
AIMS  
AND  
OBJECTIVES 
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AIMS AND OBJECTIVES 
• To assess the expression of Cycloxygenase 2 (COX-2) in invasive cervical 
carcinomas 
• To compare the clinical behaviour of cervical carcinomas and cyclooxygenase 
2 expression 
• To correlate the expression of cyclooxygenase -2 (COX2) with various 
clinicopathological variables 
• To assess the value of COX2 as a prognostic and predictive marker. 
  
  
 
REVIEW  
OF  
LITERATURE 
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REVIEW OF LITERATURE 
 
 
ANATOMY:[3,4] 
The cervix (in Latin means neck) is the lowermost portion of uterus, that 
protrudes into the upper part of vagina. In an adult nulligravida, the cervix 
measures about 2.5 – 3 cm in length, and is positioned slightly downward and 
backward. Cervix is divided into two portions:  
1. Portio vaginalis – the part that is protruding into the vagina 
2. Supravaginal portion – the part that is lying above vaginal vault. 
Ectocervix or exocervix is the outer part of portio vaginalis. The part 
related to endocervical canal is the endocervix. The opening of endocervical 
canal to the ectocervix is the external os& the upper limit of endocervical canal 
is the internal os. The portio vaginalis is divided into anterior and posterior lips. 
The cervix is supplied by uterine arteries. Venous drainage parallels 
arterial system. Lymphatics of cervix collect into two lateral plexuses near the 
isthmus & gives rise to 4 efferent channels coursing towards external iliac 
nodes & obturator nodes, hypogasrtic & common iliac nodes, & nodes on 
posterior wall of urinary bladder. The cervix is innervated chiefly in the 
endocervix& peripheral deeper portions of ectocervix. This is the reason for the 
inner two third of portio vaginalis to be relatively insensitive to pain. 
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 Figure showing thelymphatic drainage and blood supply of cervix 
 
 
HISTOLOGY OF CERVIX:[3,4] 
Cervix is made up of a mixture of fibrous, elastic and muscular tissue 
which is lined by columnar epithelium and squamous epithelium. Ectocervix is 
lined by mature non-keratinizing stratified squamous epithelium. It has 3 
zones: 
1. Germinal/ Basal/ Parabasal/ cell layer – helps in continuous epithelial 
renewal 
2. Mid zone/ Stratum spinosum – the prominent part of cervical epithelium 
3. Superficial zone – contains the most mature cells. 
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The lining of endocervix a single layer of columnar epithelial cells, 
which also line the underlying glands. These cells have finely granular 
cytoplasm which is filled with mucin and basally placed nuclei. Dendritic cells 
and lymphocytes are also seen in the epithelium and  stroma of the ectocervix 
and endocervix. 
Transformation zone is the region between original squamocolumnar 
junction & the functional/ physiologic/ new squamocolumnar junction. This 
zone is characterised histologically by the presence of metaplastic epithelium. 
Virtually all cervical squamous epithelial neoplasia arises at the transformation 
zone. 
Figure showing normal ectocervical stratified squamous epithelium. 
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Cervical carcinoma is one of the leading causes for cancer related deaths 
in Indian women[5]. The most important etiological factors responsible for the 
development of carcinoma of cervix and its precursor lesions are chronic 
infection with human papilloma virus (HPV)[3]and also early age of first sexual 
intercourse[4]. 
It has been proven that carcinoma of cervix almost always is preceded 
by precursor lesions. In 1886, Sir John Williams recognised that areas adjacent 
to invasive squamous cell carcinoma showed non-invasive dysplastic 
changes[6]. Later, in 1990, Cullen found out that these non-invasive lesions 
resemble invasive carcinoma histologically[7]. These lesions were later studied 
in detail & were designated as cervical intraepithelial neoplasia (CIN) and are 
the precursor lesions of invasive cervical carcinoma. 
This knowledge has led to the development of various screening 
procedures to detect the precancerous lesions at an early stage so that it can be 
treated effectively and thus preventing their progression to invasive cancer. 
With the effective use of these screening procedures carcinoma of cervix has 
now become one of the preventable causes of cancer morbidity and mortality. 
Today the incidence of carcinoma of cervix, predominantly the squamous cell 
type is showing a steady decline worldwide. 
It is also anticipated that the widespread use of HPV vaccination will 
help in further reduction of the incidence of this cancer in near future. 
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SCREENING FOR CARCINOMA OF CERVIX 
 Screening for carcinoma of cervix includes: 
• Cervical cytology – conventional (pap smear) 
• Cervical cytology – liquid based preparation 
• HPV testing 
• Colposcopy – VIA, VILI 
• Cervical biopsy 
• Immunomarkers 
Papaniculaou tests / Pap test was introduced as a screening method for 
carcinoma of cervixabout half a century ago. It was first done by George 
Papaniculaou[8]. Even today, it is considered as the most effective screening 
procedure for detection of a malignancy. Introduction of pap test has played a 
crucial role in decreasing the incidence of cervical carcinoma worldwide. 
Pap test is a simple, less expensive, easy to perform, minimally invasive 
screening procedure that can be done as an out-patient procedure. Ayers 
spatula, which is a wooden spatula with bifid end, is used to take scrapings 
from the transformation zone of the cervix, which is then smeared on glass 
slides. These glass slides are immediately fixed in alcohol. The fixed slides are 
stained using Papanicolau stain and examined under the microscope. 
Several advances have been introduced in cervical cytology techniques 
including the method of collection of sample, evaluation of cytological smears 
and classification system used for reporting these smears.  
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The conventional method of pap smear has been replaced recently by 
liquid based cytology. In this method, the sample is collected with the help of a 
cervical brush, which is transferred into a liquid fixation solution and sent to 
the laboratory. In the laboratory, the sample is centrifuged and the button is 
used to make an even smear which is stained and viewed under a microscope. 
Previously, yearly screening was recommended for women of age 21 – 65 
years. But according to latest guidelines by American Cancer Society[9]: 
• Screening for carcinoma of cervix should be started at the age of 21. 
• Women of age 21-29 years should undergo screening once in every 3 
years 
• Women in age group of 30 – 65 years should do both pap test and HPV 
test once in every 5 years, or a pap test alone in every 3 years. 
• Women of age more than 65 years, who had regular screening with 
normal results need not be screened further. 
The Bethesda system was introduced in 1988 to provide uniform 
guidelines for reporting cervical cytology. This was later revised in 1991 and 
2001[10]. Terence J Colgan has discussed the various sections of the Bethesda 
system in 2001[11]. The Bethesda system 2001 is given in annexure No.1. 
 Testing for HPV infection is another important screening procedure for 
carcinoma of cervix. Most of the HPV infections are transient at 1-3 years 
interval and only persistent infection has the risk of progression to cervical 
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cancer. Risk of HSIL/cancer after 3 years is not significantly higher than the 
risk after 1 year. Hence 3 years interval can be given between screening visits. 
 HPV testing is not needed in the 21-29 year group because the 
prevalence of carcinogenic HPV in early 20’s is 20%, most of which disappear 
without intervention. HPV testing in this age group creates unnecessary anxiety 
and intervention and hence avoided. 
 HPV co-testing is added in 30-65 year age group because of increased 
prevalence of CIN III in this age group. Addition of HPV co-testing also 
reduces the number of colposcopies. However this cannot be done in all areas 
because of financial restrictions and hence cytology alone every 3 years is also 
acceptable in this age group. 
 
RISK FACTORS FOR CARCINOMA OF CERVIX[3,5] 
The risk factors associated with the various precancerous lesions and 
carcinoma of cervix are: 
• Infection with high risk subtypes of Human Papilloma Virus 
(HPV)[12] 
• Multiple sexual partners 
• Age at first sexual intercourse 
• Lower age at first pregnancy 
• Multi-parity 
• Lower socioeconomic status 
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• Smoking[13] 
• Immunosuppression 
• Human immunodeficiency virus 
• Sexually transmitted disease 
• Nutritional deficiency 
• Use of oral contraceptive pills 
• Inadequate screening 
Of all the above, the most important ones are infection with high risk 
subtypes of HPV and inadequate cervical cancer screening. 
The presence of other risk factors like immunosuppression, smoking, 
long term OCP use in women with high risk types HPV infection doubles or 
triples the risk for development of high grade squamous intraepithelial lesion 
and invasive malignancy[13]. 
The positive association between cigarette smoking and development of 
cervical carcinoma has been reported in several studies[14]. 
A meta-analysis of 28 studies on the association of oral contraceptive 
pill use and cervical cancer development demonstrated that relative risk for 
invasive cervical carcinoma increased with increasing duration of OCP use[15]. 
Studies have proven the role of nutritional deficiency, especially of 
micronutrients like retinol, folate, vitamin E in cancer development[16]. 
Immunosuppression, which may be due to HIV infection, or post organ 
transplant or due to acquired or congenital immunodeficiency syndromes is a 
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well-established risk factor for development of cervical intraepithelial 
neoplasia as well as invasive cervical carcinoma. 
Low socio economic status is associated with poor hygiene, early sexual 
intercourse, micronutrient insufficiencies, increased comorbid conditions, 
which all are proven risk factors for the development of cancer cervix. 
 
ASSOCIATION OF HPV WITH CARCINOMA OF CERVIX 
Carcinoma of cervix is unique among human cancers because it is the 
first carcinoma found to be directly attributable to the effects of an infectious 
agent. This was first discovered by Dr. Herald zurHausen, for which he was 
awarded the Nobel Prize in medicine in 2008[17]. 
Human papilloma virus belong to the family Papillomaviridae[18]. 
Papillomaviruses are epitheliotropic viruses, which means they infect 
predominantly the skin and mucous membranes producing epithelial 
proliferations at the site of infection. They are double stranded DNA viruses. 
There are 118 distinct types of papilloma viruses[17]. HPV, in addition to cervix 
cancer, is also known to be associated with vulval, anal, penile and some of the 
head and neck squamous cell carcinomas[19]. 
A study done to detect the incidence of HPV in cervical carcinomas by 
multiple molecular techniques detected that the prevalence of HPV in cancer 
cervix across the world is 99.7%[20] 
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The HPV types that are associated with invasive carcinoma of cervix 
include HPV 16, 18, 31, 35, 33, 39, 45, 51, 56, 58, 59, 66 and 52. Among these, 
the most commonly associated HPV type is HPV 16, followed by HPV 18[21]. 
The initial site of HPV infection is the basal cell of the ectocervical 
epithelium. HPV can reside in the epithelial cells in two different biological 
forms. One is latent infection, in which no infectious virions are produced and 
the other is productive infection, in which numerous infective virions are 
produced.  
 
 
Figure showing the effect of HPV infection in cervical epithelium 
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The cytological features of virus infected cells include: 
• Koilocytosis 
• Acanthosis 
• Anisocytosis 
• Perinuclear cytoplasmic vacuolization 
• Multinucleation 
•  Nuclear atypia.  
 
PRECURSOR LESIONS OF SQUAMOUS CELL  
CARCINOMA OF CERVIX 
 The 3 different systems of classification of precursor lesions are 
compared in the following table. 
 
Older classification 
 
WHO classification 
 
Bethesda system 
 
Mild dysplasia 
 
CIN 1 
Low grade squamous 
intraepithelial lesion 
(LSIL) 
 
Moderate dysplasia 
 
CIN 2 
High grade squamous 
intraepithelial lesion 
(HSIL) 
Severe dysplasia/ 
Carcinoma in situ 
 
CIN 3 
 
HSIL 
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 The term cervical intraepithelial neoplasia (CIN) was introduced by 
Richart who proposed that all the precursor lesions of cervical carcinoma are 
monoclonal proliferations and represent a single disease process[22]. According 
to him, CIN 1 is synonymous to mild dysplasia, CIN 2 to moderate dysplasia 
and CIN 3 to severe dysplasia/ carcinoma in situ. 
 Later it was proved that the invasive carcinoma of cervix (squamous and 
adenocarcinoma) are caused by infection of anogenital tract by high risk types 
of HPV[23,24]. Hence a new model of cervical carcinogenesis was 
developed[25,26,27], which involves: 
1. Infection with high risk types of HPV 
2. Progression to precursor lesion 
3. Invasion 
Subsequently, the new Bethesda system was introduced which categorised 
the lesions into two (Two tier system)[28,29]: 
1. LSIL (Low grade squamous intra epithelial lesion) – for those lesions 
initially called CIN 1. 
2. HSIL (High grade squamous intra epithelial lesion) – for those lesions 
initially called CIN 2 & CIN 3 
 
  
16 
 
CLINICAL FEATURES 
• Early invasive cancers are usually asymptomatic and are detected during a 
routine screening by pap smear. 
• As the tumor increases in size, patient may complain of irregular vaginal 
bleeding, metrorrhagia, or discharge per vaginum. 
• Another common presenting symptom is dyspareunia (pain during sexual 
intercourse) 
• When the tumor extends to the parametrium, it can cause obstruction of 
the ureters causing hydronephrosis, anuria, or uremia.  
• Pelvic side wall extension of the tumor causes sciatic pain or less 
frequently lymphedema of lower extremities. 
• Bladder involvement of the tumor can cause increased frequency of 
micturition, hematuria, bladder pain, urinary retention or vesicovaginal 
fistula. 
• Rectal infiltration by tumor can cause pain, bleeding per rectum, 
rectovaginal fistula. 
• Patient may sometimes present with symptoms of distant metastasis like 
cervical node enlargement, hemoptysis etc. 
• Non-specific symptoms like weakness, pallor, weight loss may also be the 
presenting symptoms in some patients. 
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DIAGNOSIS 
Diagnosis of cervical carcinoma is made combining the findings of 
history, physical examination, imaging and biopsy.  
• History – history of irregular vaginal bleeding, post coital bleeding or 
post-menopausal bleeding can suggest carcinoma of cervix in a 
multiparous women from a lower socioeconomic status. 
• General examination to look for pallor, lymph node enlargement or any 
signs of metastatic disease. 
• Speculum examination to look for any growth in the cervix, type of 
growth (ulcerative / nodular / papillary), bleeding on touch. 
• Per vaginal examination to look for the extend of growth, parametrial 
involvement, vaginal involvement, seedling in pouch of Douglas, 
involvement of ovary 
• Pap smear – to look for malignant cells in cervical cytology 
• Per rectal examination – to look for rectal involvement in advanced 
diseases. 
• Cystoscopy – to look for bladder mucosal involvement by the tumor. 
• Human Papilloma Virus (HPV) testing – to detect the specific viral DNA 
or RNA. 
• Endocervical curettage – to detect the presence of malignant cells. 
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• Ultrasound, CT, MRI – to look for extend of parametrial invasion, ureteric 
involvement, hydrouretronephrosis, lymph node involvement, bowel and 
bladder extension of tumor. 
• Chest X-ray, CT chest – to look for evidence of lung metastasis 
• Biopsy from cervix – this is the confirmatory test for the diagnosis of 
carcinoma of cervix. Biopsy can also detect the histological type of 
carcinoma. 
 
CLINICAL STAGING OF CARCINOMA OF CERVIX 
 Carcinoma of cervix is unique in that the staging is done clinically. The 
various parameters for staging include: 
• Size of the tumor 
• Parametrial involvement 
• Involvement of vagina 
• Presence/absence of hydronephrosis or non-functional kidney. 
• Bladder or rectal involvement 
• Presence/absence of distant metastasis 
Clinical staging is done by: 
• Physical examination 
• Ultrasound  
• Intravenous pyelogram 
• Cystoscopy 
19 
 
• Proctoscopy 
• Chest X-ray 
The presence of lymph node metastasis or margin involvement detected 
after surgery by histopathological examination will not alter the stage. 
 
GROSS: 
• Early lesions – focal induration, ulceration or a nodular lesion, mostly 
localized within the transformation zone. 
• Advanced lesions may be endophytic or exophytic. 
• Endophytic lesions may be ulcerated or nodular, and usually invade deep 
into the cervical stroma producing a barrel shaped cervix. 
• Exophytic lesions have a polypoidal, fungating or papillary appearance. 
 
WHO classifies invasive cervical carcinoma broadly into: 
¾ Squamous cell carcinoma  
¾ Adenocarcinoma  
¾ Other epithelial tumors 
o Adenosquamous carcinoma 
o Neuroendocrine tumors 
o Un-differentiated carcinoma 
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INVASIVE SQUAMOUS CELL CARCINOMA OF CERVIX 
 The commonest histologic subtype of carcinoma of cervix is squamous 
cell carcinoma and accounts for 70-80% of all cervical carcinomas[30]. The 
most important etiological factor responsible for development of carcinoma of 
cervix is infection with high risk subtypes of HPV, especially HPV 16 and 
HPV 18[31]. The other types of HPV implicated in the cervical carcinogenesis 
include HPV 31, 33, 35, 45, 52 & 58[32]. 
 The most commonsymptoms of patients having an invasive cervical 
carcinoma are abnormal vaginal bleeding and post coital bleeding. Other 
symptoms include intermittent spotting, serosanguinous discharge, pain, 
weakness, weight loss, rectal pain or hematuria. 
 Grossly, early carcinomas present as localized growth within the 
transformation zone, whereas advanced cases present as exophytic or 
endophytic tumors that invade into cervical stroma and into the adjacent 
structures. 
 Microscopically SCC is characterized by the anastomosing cords and 
tongues of neoplastic squamous epithelial cells infiltrating the stroma. Current 
WHO classification divides invasive SCC into 2 groups: 
1. Keratinizing SCC – keratin pearls are present within the epithelium 
2. Non- keratinizing SCC – neoplastic cells with individual cell 
keratinization &no keratin pearl formation. 
21 
 
The grading system for SCC was proposed by Broders in 1920[33]. The 
currently used grading system is a modification of the original form and 
consists of 3 groups: 
1. Well differentiated SCC (Grade 1) –Characterised by abundant keratin, 
deposited in the form of keratin pearls in between neoplastic epithelial cell 
nests. The cells have abundant eosinophilic cytoplasm, large, irregular and 
hyperchromatic nuclei and well developed intercellular bridges. Mitotic figures 
are seen predominantly near the periphery of advancing epithelial cell nests. 
2. Moderately differentiated SCC (Grade 2) - Neoplastic cells show more cellular 
pleomorphism than grade 1 tumors with less abundant cytoplasm and large 
irregular nuclei. Intercellular bridges and cellular borders appear indistinct. 
Here keratin pearl formation is seen only rarely, but there will be individual 
cell keratinization present towards the centre of tumor cell nests. More 
numerous mitotic figures are noted than in grade 1 SCC. 
3. Poorly differentiated SCC (Grade 3) - composed of cells with scant indistinct 
cytoplasm and hyperchromatic oval nuclei. Definite evidence of squamous 
differentiation manifested by intercellular bridges or keratinization are difficult 
to find. Abundant areas of necrosis and numerous mitotic figures are seen.  
The treatment options for SCC of cervix include surgery, radiation, 
chemotherapy or combinations of these 3. 
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ADENOCARCINOMA OF UTERINE CERVIX 
Adenocarcinoma includingadenosquamous carcinoma comprises 10-
15% of all cervical malignancies[34]. Though the incidence of cervical 
carcinoma is decreasing worldwide, many studies reveal the increasing rate of 
adenocarcinoma in young women[35,36,37]. 
Most of the risk factors for cervical adenocarcinoma are similar to that 
ofSCC[38,39]. HPV 18 is more commonly associated with cervical 
adenocarcinoma than with squamous cell carcinoma[40,41]. 
Majority of cervical adenocarcinomas arise in the transformation zone. 
Patients usually present with vaginal discharge, abnormal vaginal bleeding or 
pelvic pain. 
Grossly the lesion may be a fungating, polypoidalor papillary mass or a 
diffusely enlarged or nodular cervix. 
Microscopically, the most common histologic type is the usual type of 
cervical adenocarcinoma, which comprises more than 75% of cervical 
adenocarcinomas. The cells are columnar in shape having amphophilic or 
eosinophilic apical cytoplasm and elongated, hyperchromatic, pleomorphic 
nucleuswith coarse chromatin. Mitotic figures and apoptotic bodies are 
frequent. 
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Histological grading of adenocarcinoma is: 
¾ Well differentiated ADC – less than 10% of tumor is formed by solid 
sheets of cells. 
¾ Moderately differentiated ADC– 11 – 50% of tumor is formed by solid 
sheets of cells. 
¾ Poorly differentiatedADC – more than 50% of tumor is made up of solid 
sheets of cells. 
True endometrioid-type endocervical adenocarcinoma accounts for 
about 10% of all cervical adenocarcinomas. 
Mucinous Adenocarcinoma can be of 3 types: 
1. Endocervical-Type Mucinous ADC 
2. Intestinal-Type Mucinous ADC 
3. Signet-Ring Cell-Type Mucinous ADC 
The term ‘minimal deviation adenocarcinoma’ was introduced in 1975 
by Silverberg and Hurt [42].It is an extremely well - differentiated variant of 
cervical adenocarcinoma.Here most of the tumor cells lack cytologic features 
of malignancy.  These account for 1–3% of all cervical adenocarcinomas. 
 Villoglandular adenocarcinoma is another well-differentiated type of 
cervical adenocarcinoma occurring predominantly in young women and is 
associated with an excellent prognosis[43,44]. 
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 Endometrioid adenocarcinomas of the cervix resemble primary 
adenocarcinomas of uterine corpus. The cells of endometrioid 
adenocarcinomas are stratified and have oval nuclei with lesser amount of 
cytoplasm than the cells of usual type of endocervical adenocarcinomas. 
 Clear cell carcinomas comprise around 4% of cervicaladenocarcinomas 
.Postmenopausal women are more commonly diagnosed with this variant. Most 
of the clear cell carcinomas of cervix diagnosed during the period from 1970 to 
late 1990s were related to exposure to diethylstilbestrol (DES) prenatally and 
were more common in younger women[45,46]. Three basic microscopic patterns 
are seen in clear cell carcinoma namely solid, tubulocystic and papillary 
patterns.Tumor cells have well defined cell margins, moderate to abundant 
clear cytoplasm (due to accumulation of glycogen) and high grade nuclei. The 
nuclei may be seen projecting into the lumen of cysts and tubules forming 
‘hobnail cells’. 
ADENOSQUAMOUS CARCINOMA  
 These tumors are composed of an admixture of malignant glandular and 
squamous cells. Adenosquamous carcinomas comprises 3.6% to 25% of all 
cervical cancers[47,48,49,50]. The squamous component are usually well 
differentiated with keratin pearl formation or cells with individual cell 
keratinization.Adenocarcinomatous component may or may not be well 
differentiated, and if present in relatively small amounts, can easily be 
overlooked. A recent study have shown that the squamous and glandular 
components are monoclonal in origin and they originate from a common 
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precursor cell[51]. Metastasis to pelvic lymph nodes is twice more common in 
adenosquamous carcinoma than in pure adenocarcinomas or squamous cell 
carcinomas. Despite this, the prognosis is not significantly worse than those 
with squamous cell carcinomas. 
 Glassy cell carcinoma is poorly differentiated variant of adenosquamous 
carcinoma and accounts for less than 1% of all cervical cancers. Grossly they 
produce a barrel-shaped cervix. Microscopically they are composed of large 
uniform polygonal cells with distinct cell membranes, ground glass-type 
cytoplasm, and prominent nucleoli. The stroma is characteristically heavily 
infiltrated by lymphocytes, plasma cells and eosinophils. These are extremely 
aggressive tumors and response to radiation & surgery are very poor.[52,53]. 
PROGNOSTIC FACTORS 
• Clinical criteria:[54,55,56] 
o Age  
o Stage of the disease 
o Lymphatic spread 
o Vascular invasion 
• Histopathological criteria:[57,58,59] 
o Tumor size 
o Depth of invasion 
o Parametrial invasion 
o Nodal status 
o Lymphovascular invasion 
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• Human papilloma virus DNA status 
• Genetic predictive factors 
o c-erb B 
o c-MYC 
Younger women are found to have a better prognosis when compared to 
older women[60]. 
Stage of the disease is the most important prognostic factor for 
carcinoma of cervix. The stage, in turn, is depended on size of tumor, depth of 
invasion, parametrial infiltration and nodal status. 
Several studies have proved that the 5 year survival rate of patients with 
smaller tumors and less of invasion into the cervical stroma is significantly 
increased than those with larger tumors& more invasion[61]. 
In patients with lymphovascular invasion, the 5 year survival rate was 
found to be decreased when compared to those with no 
lymphovascularinvasion[59]. Also, the presence of lymphovascular invasion was 
found to be associated with 4 -5 times more risk of lymph node metastases[57], 
and hence a decreased 5 year survival rate[62]. 
The parametrial involvement by tumor is associated with lymph node 
metastasis, local recurrence & poor survival rate[61,63]. 
Studies assessing the effect of HPV types on prognosis have shown that 
detection of HPV 18 DNA was associated with a poor prognosis and increased 
risk of death irrespective of the presence or absence of other prognostic 
27 
 
factors[64,65]. Studies have also shown that those patients who are infected with 
multiple HPV types are more resistant to radiation treatment when compared to 
those infected with a single HPV type[66,67]. 
Amplifications of c-erb B-2 and c-myc are found to be associated with 
poor prognosis[68,69]. 
 
PROGNOSTIC BIOMARKERS 
 The role of immunohistochemistry in detection of various prognostic 
biomarkers in cervical carcinoma has been studied extensively. The various 
biomarkers that have been studied so far include 
• Ki – 67 
• LRIG1 
• COX – 2 
• EGFR 
• HER 2 
• VEGF 
• D2-40 
• Hyaluronan receptor – 1 
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ROLE OF COX-2 IN CERVICAL CARCINOMA 
 Cyclooxygenase (COX), is an enzyme that catalyzes the conversion of 
arachidonic acid to prostaglandins, thromboxane &levuloglandins[70]. It is also 
designated as prostaglandin endoperoxide synthase (PES).COX was first 
identified about 30 years ago. Two isoforms of COX has been identified. 
1. COX-1 – produced constitutively in many tissues and is referred to as the 
house keeping gene. 
2. COX-2 – inducible enzyme synthesised in sites of inflammation[71]. 
 
 
 
   COX-1 
   COX-2 
           Prostaglandin G2 
 
 
 
 
               PGF2α   PGD2    PGE2    PGI2 TXA2 
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    COX-2 is an inducible gene or an early response gene. The various 
factors that induce COX2 expression include various growth factors, 
oncogenes, prostaglandins, tumor promoters and carcinogens[72]. COX-2 
overexpression has been well documented in colorectal carcinomas[73]. High 
COX-2 expression has also been demonstrated in various other lesions like 
high grade squamous cell carcinoma of oesophagus[74], pre-neoplastic lesion of 
lung and pre-invasive lesions of breast[75], adenomatous and metaplastic lesions 
of stomach[76], pre-invasive neoplasms of bladder[77] and pancreas[78]. 
 COX 2 increases local prostaglandin production in tumor cells and 
induces tumorigenesis by affecting cellular adhesion, mitogenesis, apoptosis, 
angiogenesis and immune surveillance. Studies have proven the fact that COX2 
inhibits apoptosis. 
 Studies on the expression of COX-2 in carcinoma of cervix are 
relatively few. Sukumvanich et al[79] and Kulkarni et al[72] have shown that the 
expression of COX-2 increases with increasing severity of dysplasia to invasive 
carcinoma. Also high COX-2 expression was found to be associated with 
parametrial invasion &lymph node metastasis in stage IBtumors[80]. High 
COX-2 expression also correlated with worse prognosis in terms of overall 
survival & disease free survival in patients treated with radiotherapy[81]. A 
positive association of presence of lymphovascular emboli & COX-2 
expression have also been demonstrated[82]. These studies signify the role of 
COX-2 as a prognostic marker. 
30 
 
 However, some studies have failed to demonstrate a significant 
correlation between COX-2 expression and tumor response in post 
radiotherapy patients[83]. 
 Kulkarni et al demonstrated that EGFR and its ligands EGF & TGF-α 
markedly induce COX-2 in cervical cancer, which suggest that deregulated 
signalling through EGFR may account for the increased COX-2 expression. 
EGF exerts its action by stimulating RAS & P13 signalling, which in turn leads 
to activation of MAPKs and an increased AP-1 activity that are responsible for 
induction of COX2[84]. 
 In a meta-analysis of 23 studies with 1477 cervical carcinoma patients, it 
was found that COX-2 over expression was associated with an unfavourable 
prognosis and correlated with chemoradiation resistance in cervical carcinoma, 
which could potentially help to stratify patients for further treatment options[85]. 
 Studies using selective COX2 inhibitors (celecoxib) in patients with 
carcinoma of cervix have shown a reduced expression of COX-2, CD31 & Ki-
67 and a decrease in microvesseldensity[86]. But clinical trials using celecoxib 
in patients with advanced cervical carcinoma have failed to demonstrate any 
therapeutic effect[87,88]. 
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OTHER BIOMARKERS IN CERVIX CARCINOMA 
1. Ki-67 – studies have shown that high Ki-67 index intumor cells was 
associated with poor prognosis inlate stage cervical carcinoma[89]. 
2. LRIG1(Leucine rich repeats & immunoglobulin like domains-1) – 
expression of this transmembrane protein was associated with favourable 
prognosis in patients with early stage cervical carcinoma[89]. LRIG1 was 
shown to exert its effects by restricting growth factor signalling and 
degrading the EGFR and thereby inhibiting the cellular oncogenes MET 
& RET. 
3. EGFR – the expression of EGFR in cervical carcinoma is found to be 
associated with a poor prognosis[90]. EGFR acts y promoting RAS & 
P13K signalling, leading to activation of MAPKs, which in turn induce 
the expression of COX-2. 
4. HER-2 (EGFR-2) – HER-2 expression is also found to be associated with 
a poor prognosis. 
5. D2-40(marker for lymphatic vessel endothelium) – Expression of D2-40 
which correlates with peritumoral lymphatic vessel density has shown a 
significant correlation with lymph node metastasis, high tumor stage & 
poor survival[91]. 
6. Hyaluronan receptor-1 (which is also an antibody against lymphatic 
vessel endothelium) – increased expression of this antibody was 
associated with lymphatic vessel invasion & lymph node metastasis in 
early stage cervical cancer[92]. 
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7. VEGF (Vascular Endothelial Growth Factor) – overexpression of VEGF 
is associated with poor prognosis in many cancers, including cervical 
cancer. High VEGF expression correlates with increased risk for lymph 
node metastasis and high stage of disease[93]. High VEGF expression & 
increased tumor vascularization are demonstrated to be independent 
predictors of shorter disease-free survival & overall poor survival[94]. 
 
TREATMENT 
The treatment of cervical carcinoma depends on the stage of disease. The 
various treatment options include the following: 
• Carcinoma in situ / CIN III – local ablation or excisional procedures like 
cryosurgery, laser excision, loop electrosurgical excision procedure 
(LEEP). If family is completed, then simple hysterectomy is usually 
recommended. 
• Stage IA1 – simple / radical hysterectomy without radical lymph node 
dissection. For young patients who would like to retain fertility can be 
treated with conisation procedures with close follow up using pap smears, 
colposcopy and endocervical curettage. 
• Stages IA2, IB, IIA – treatment options include radical hysterectomy with 
bilateral pelvic lymph node excision, or combination of external beam 
radiation with brachytherapy. For stage IA2 patients who wish to retain 
fertility, radical vaginal trachelectomy can be done along with pelvic 
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lymph node dissection. For patients with positive nodes or positive 
surgical margins, post-operative radiation can be given.  
• Stages IIB, III, IVA – for these locally advanced diseases, treatment 
options include radiotherapy or combined radiation and chemotherapy 
(cisplatin based) 
• Stage IVB and recurrent carcinomas – palliative therapy. For pain and 
vaginal bleeding, radiotherapy can be given. For disseminated diseases, 
chemotherapy is given. For local recurrences, chemoradiation is the usual 
treatment option, whereas for recurrence outside pelvis, combination 
chemotherapy is usually recommended. 
• Cervical carcinoma in pregnancy – carcinoma of cervix is the most 
common gynaecological carcinoma in pregnancy. For very early stage 
carcinomas, pregnancy can be continued, and after delivery specific 
treatment for carcinoma can be given. For advanced cases, it is better to 
terminate the pregnancy and treat the malignancy. If the patient wishes to 
continue with her pregnancy, then pregnancy should be terminated by 
caesarean section as soon as the baby becomes viable. 
  
IMMUNOHISTOCHEMISTRY (IHC) 
IHC is a molecular technique which was first described by Dr.Albert 
Coons in 1941. The original method consisted of an antibody developed in 
rabbits and then tagged with a fluorescent probe. It was mixed with tissue 
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sections  and  examined  using  a  fluorescent  microscope  after  a  period  of 
incubation.  Since then, numerous advancements  have  been  made[95]. 
The most commonly used techniques are the peroxidase -antiperoxidase 
immune complex  method  developed  by  Sternberger  in  1970  and  the  
biotin avidinimmunoenzymatic technique developed byHeitzman and Richards 
in 1974[96,97]. 
ANTIGEN RETRIEVAL 
 Shi et al in 1991developed the antigen retrieval technique, in which he 
used a heating method at high temperatures to bring out the antigenicity of the 
tissue which had been masked by formalin fixation.  
Antigen retrieval can be done by proteolytic induced epitope retrieval or 
heat induced epitope retrieval 
 
HEAT INDUCED EPITOPE RETRIEVAL 
 In  this  technique,  tissue  sections  are  placed  in  the  retrieval  
solution which is heated for varying period of time that leads to the breakdown  
of protein  cross-links  which  are  formed  during  fixation  with  formalin  and 
recovers the tissue antigenicity[98]. 
 Commonly used heating devices are the pressure cooker, microwave 
oven, autoclave, steamer and water bath.  Heating is usually done for about  
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20 minutes followed by 20 minutes of cooling.  The retrieval solution 
commonly used is the Citrate buffer with pH 6.0. 
 
PROTEOLYTIC INDUCED EPITOPE RETRIEVAL[99] 
 Proteases liketrypsin, proteinase K, chymotrypsin and pepsin are  
usedfor  restoring  the  tissue  antigenicity.  However,  the  limitation  of  this 
technique  is  thatsome  epitopes  are  destroyed  during  this  process  and 
therefore alter the tissue morphology. 
 
TARGET ANTIGEN DETECTION METHODS 
 After  addition  of  specific  antibodies  to  the  antigens,  next  step  is  
to visualize the antigen antibody reaction complex. The methods employed are 
the direct and the indirect methods. The direct method is a one -step staining 
procedure in which a labelled antibody directly reacts with the antigen in the 
tissue sections. Most commonly used labels are fluorochrome, horse radish 
peroxidase and alkaline phosphatase. Although this method is simple, rapid, 
and uses only one antibody, the sensitivity is lower. This is because signal 
amplification  is  less,  and  therefore  it  is  not  as  commonly  used  when 
compared to the indirect methods. 
 In the indirect method, first layer is formed by an unlabelled primary 
antibody which binds to the target antigen. Then, a second layer  is formed by  
using  a  labelled  secondary  antibody  that  reacts  with  the  primary  
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antibody. This technique is more sensitive than the direct method because of 
better signal amplification. This is due to the binding of several secondary 
antibodies with conjugated fluorochrome to each primary antibody. Another 
advantage with this method is that it uses only a small number of secondary 
antibodies[100]. 
  
  
 
MATERIALS  
AND  
METHODS 
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MATERIALS AND METHODS 
 This study is a  retrospective  descriptive  study  of invasive cervical 
cancer conducted  in  the  Department  of  Pathology, Institute of Obstetrics and  
Gynaecology, Egmore, Chennai during the period from January 2014 to 
December 2014. 
 A total of 3427 specimens were sent to the Department of Pathology, 
Institute of Obstetrics and Gynaecology, Egmore, Chennai during the period of 
Jan 2014 to Dec 2014 for histopathological examination. 
 
 Out of that 511 cases were cervix cancer, which includes 12 Werthims 
hysterectomies and 499 cervix biopsies. Among those, 50 cases were selected 
for our study. Among those 50 cases, 9 cases were hysterectomies and 41 were 
cervix biopsies.  
 
SOURCE OF DATA 
 The cervix carcinoma cases diagnosed at the Department of Pathology, 
Institute of Obstetrics and Gynaecology, Egmore, Chennai during the period of 
Jan 2014 to Dec 2014, which have been sent by the Department of 
Gynaecology. 
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INCLUSION CRITERIA: 
1. All Werthims hysterectomy specimens of cervical carcinomas. 
2. All invasive cervical carcinomas, including squamous cell carcinomas, 
adeno carcinomas, adenosquamous carcinoma, clear cell carcinoma and 
undifferentiated carcinoma. 
3. All small biopsy specimens of cervical lesions, proved 
histopathologically as malignant. 
 
EXCLUSION CRITERIA: 
1. All small biopsy specimens of cervical lesions, proved 
histopathologically as benign or non-neoplastic lesions. 
2. All Werthims hysterectomy specimens with no evidence of residual 
tumor. 
3. Post radiotherapy or chemotherapy specimens. 
4. Recurrent tumors. 
 
METHOD OF DATA COLLECTION 
 For the 50 patients included in the study, detailed history regarding age, 
presenting symptoms, parity and menstrual status were obtained. Patients were 
examined clinically for pallor, lymphadenopathy and mass per abdomen. 
Details of per speculum, per vaginal and per rectal examinations were noted. 
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Reports of cystoscopy, ultrasound abdomen & pelvis, computerised 
tomography of abdomen & pelvis were also noted.  
 Tissues were fixed in 10% neutral buffered formalin, processed and 
embedded in paraffin. 4  μm  thick  sections  of  the  paraffin  tissue  blocks  
were  cut  and  stained with eosin and hematoxylin. Slides were collected from 
slide filing and were reviewed. The original diagnosis of Invasive malignancy 
with Histological Grading according to WHO criteria for classification was 
made by the Senior Pathologist in almost all cases. 
 Tumours were sub typed as adenocarcinoma  if  it  has features of  gland 
formation, squamous cell carcinoma if it has features of  keratinazation or 
intercellular bridges, adenosquamous carcinoma if it had features of both adeno 
and squamous cell carcinomas, clear cell carcinoma if they had cells with 
abundant clear cytoplasm, hyperchromatic and pleomorphic nuclei that project 
into the lumen of cysts and tubules to form ‘hobnail cells’, and undifferentiated 
carcinoma if no specific differentiating features are present. 
 50 cases of carcinoma of cervix were selected randomly and included 
for further evaluation and comparing the clinical and morphological parameters 
and to study the efficiency of marker (COX2). 
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IMMUNOHISTOCHEMICAL EVALUATION: 
 Immunohistochemical analysis of marker COX2 was done in paraffin 
tissue blocks using super sensitive HRP polymer system based on non-biotin 
polymeric technology. Sections of 4µ thickness were cut from the paraffin 
tissue blocks. They were transferred to gelatin coated slides. Heat induced 
antigen retrieval was done. The antigen was bound with mouse monoclonal 
antibody (PathnSitu) against COX2 protein and then detected by the addition of 
secondary antibody conjugated with horse radish peroxidase – polymer and 
Diaminobenzidine substrate. The step bystep  procedure  of  
Immunohistochemistry is given in Annexure 
Antigen Vendor Species Dilution Positive control 
COX2 PathnSitu Rabbit Ready to use Carcinoma colon 
 
CONTROL: 
Carcinoma of colon was taken as internal control for assessing COX2 
reactivity & to avoid false negative results. 
 
INTERPRETATION AND SCORING SYSTEM 
The immunohistochemically stained slides were analysed for the 
presence of reaction, cellular localization (cytoplasm and cytoplasmic 
membrane) and percentage of cells stained. 
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The immunohistochemical expression of COX-2 was graded as: 
 Negative – no staining 
 1+   -   less than 10% of tumor cells staining positive for COX-2 
 2+   -   10 -50% of tumor cells staining positive for COX-2 
 3+   -   more than 50% of tumor cells staining positive for COX-2 
 In this study, for evaluation of COX-2 greater than 10% expression of 
the tumour marker in cytoplasm and cytoplasmic membrane of tumour cells 
(2+ and 3+) is considered as positive. Cases with no areas of positive staining 
(Negative) and with less than 10% staining (1+) are considered negative. 
 
STATISTICAL ANALYSIS 
 Immunohistochemical analysis was done in paraffin embedded tissue 
samples using the statistical package for social science software version IBM 
SPSS version 20 which consisted computing the frequency counts and 
percentages for qualitative variables and mean for quantitative variables. The 
correlation between COX2 and various clinicopathological parameters was 
made and strength of association calculated using Pearson Chi square test. P 
values less than 0.05 are considered statistically significant. 
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Among the 502 small biopsies, 466were squamous cell carcinoma, 27 
were adenocarcinoma, 5 were undifferentiated carcinoma, and one each of 
clear cell carcinoma of cervix, malignant mixed mulleriantumor of cervix, 
poorly differentiated carcinoma and adenosquamous carcinoma. The squamous 
cell carcinoma and adenocarcinoma were further subcategorised into well, 
moderate and poorly differentiated grades. 
Among the 9 hysterectomies, 3 were moderately differentiated 
squamous cell carcinoma, 3 were poorly differentiated squamous cell 
carcinoma and 3 were well differentiated adenocarcinoma. 
The most common type of carcinoma of cervix was squamous cell 
carcinoma (92.36%), followed by adenocarcinoma (5.87%) 
Table 2: Histological subtypes of cervix carcinoma 
Histological subtypes No. of cases Percentage 
Squamous cell carcinoma 472 92.36% 
Adenocarcinoma  30 5.87% 
Undifferentiated carcinoma 5 0.97% 
Clear cell carcinoma 1 0.19% 
Adenosquamous carcinoma 1 0.19% 
Malignant mixed mulleriantumor 1 0.19% 
Poorly differentiated carcinoma 1 0.19% 
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Chart 6 : Incidence of carcinoma with respect to tumor size 
 
 
Since majority of cases included in the study were of higher stages, 
(stage IIIB & stage IIIA ), 64% of them had parametrial involvement, 24% 
upto the lateral pelvic wall. 36% of cases had no parametrial involvement. 
Table 7: Incidence of parametrial involvement 
Parametrial involvement No. of cases Percentage 
Parametrium free 18 36 
Parametrial invasion not 
upto lateral pelvic wall 
20 40 
Parametrial invasion upto 
lateral pelvic wall 
12 24 
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Of the total 511 cases of cervical carcinoma, squamous cell carcinoma 
was the most common type, followed by adenocarcinoma. In our study group 
of 50 cases also squamous cell carcinoma was the most common type. Among 
squamous cell carcinomas, most common was moderately differentiated grade 
(54%), followed by poorly differentiated grade (36%). 
 
Chart 11 : Histological subtypes of cervical carcinoma 
 
 
 
 
  
8%
42%
28%
8%
4% 4%
2% 2% 2%
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
W
el
l d
iff
er
en
tia
te
d 
SC
C
M
od
er
at
el
y 
 d
iff
er
en
tia
te
d 
SC
C
Po
or
ly
 d
iff
er
en
tia
te
d 
SC
C
w
el
l d
iff
er
en
tia
te
d 
A
D
C
M
od
er
at
el
y 
di
ff
er
en
tia
te
d 
A
D
C
Po
or
ly
  d
iff
er
en
tia
te
d 
A
D
C
A
de
no
sq
ua
m
ou
s 
ca
rc
in
om
a
U
nd
iff
er
en
tia
te
d 
ca
rc
in
om
a
cl
ea
r c
el
l c
ar
ci
no
m
a
 COX2 exp
staining, 1
– 50% of t
tumor cell
COX2 
Ne
<
10%
>
T
 
3
ression wa
+ when <1
umor cells
s showed p
Table
expression
gative 
10% 
 - 50% 
50% 
otal 
Chart
0%
s graded a
0% of tum
 showed p
ositive sta
 12: COX
 
 12 : COX
8%
54
s negative
or cells sh
ositive sta
ining.  
2 express
No. of ca
16 
15 
15 
4 
50 
2 express
30%
 when no 
owed pos
ining and 
ion in the 
ses 
ion in the
32%
tumor cell
itive staini
3+ when m
study gro
Per
 study gro
s showed p
ng, 2+ wh
ore than 
up 
centage 
32 
30 
30 
8 
100 
up 
Nega
<10 %
10-50
>50%
ositive 
en 10% 
50% of 
 
tive
 %
55 
 
In the study group, a correlation between age of the patients and 
histopathological diagnosis was done. It was found that in the age group of 40-
50 years, most common was squamous cell carcinoma moderately 
differentiated grade, whereas in older age groups (51 – 70 years) squamous cell 
carcinoma poorly differentiated grade was found to be more common. In the 
case of adenocarcinomas, well differentiated grade was found to be more 
common in 40-50 years age group whereas poorly differentiated grade was 
more common in older age group (51-70 years). But this was not statistically 
significant. Adenosquamous carcinoma and undifferentiated carcinoma was 
also seen in older age group (51- 60 years) and clear cell carcinoma of cervix 
was detected in a younger female (40-50 year). Since only a single case was 
present for these variants these are also statistically not significant. 
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Table 13 : Correlation between age and HPE subtypes 
 
HPE subtypes 
Age groups 
40-50 51-60 61-70 >70 Total 
Well  differentiated SCC 0 2 2 0 4 
Moderately  differentiated 
SCC 
11 6 3 1 21 
Poorly  differentiated SCC 2 7 4 1 14 
Well differentiated ADC 3 1 0 0 4 
Moderately differentiated 
ADC 
1 0 1 0 2 
Poorly differentiated ADC 0 1 1 0 2 
Adenosquamous carcinoma 0 0 1 0 1 
Undifferentiated carcinoma 0 0 1 0 1 
Clear cell carcinoma 1 0 0 0 1 
Total 18 17 13 2 50 
 
 When age of the patients was correlated with COX2 expression, it was 
found that the expression of COX2 was lesser in younger females i.e 40-50 
years age group (33.33%) when compared to females of older age group i.e age 
more than 50 years (40. 26%).  This was also statistically not significant. 
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 When the menstrual status and stage of the disease were compared, it 
was noted that menstruating females presented in early stages of the disease, 
whereas postmenopausal females presented in advanced stages of disease. This 
correlation was statistically found to be significant with a p value of 0.004.  
This indicated that younger age group females presented in the early stages of 
disease when compared to older age group females. This can be due to the 
positive impact of cervical carcinoma screening procedures and increased 
awareness of carcinoma of cervix among the general population.  
 
Table 15:Correlation between menstrual status and stage 
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When COX2 expression was correlated with vaginal involvement by the 
tumor, it was noted that tumors with vaginal involvement were showing 
increased COX2 expression than those in which vagina was free of tumor.  
Table 18 : COX2 expression and vaginal involvement 
 
COX2 
expression 
Vaginal involvement  
Total Free Upper 1/3rd 
involved 
Lower 2/3rd 
involved 
Negative 10 
(83.3%) 
14 
(58.3%) 
7 
(50%) 
31 
(62%) 
Positive 2 
(16.7%) 
10 
(41.7%) 
7 
(50%) 
19 
(38%) 
Total 12 
(100%) 
24 
(100%) 
14 
(100%) 
50 
(100%) 
 
Chart 17 : COX2 expression and vaginal involvement 
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 On comparing the COX2 expression with nodal status of the patients, it 
was noted that in all the 7 cases where no nodes were detected clinically, 
COX2 expression was negative. Among the 43 cases with enlarged nodes, 
44.2% had positive COX2 expression. This was found to be statistically 
significant with a p value of 0.026. 
Table 19: COX2 expression and nodal status 
 
COX2 expression 
Nodal status  
Total 
Absent Present 
Negative 7(100%) 24(55.8%) 31(62%) 
Positive 0(0%) 19(44.2%) 19(38%) 
Total 7(100%) 43(100%) 50(100%) 
 
Chart 18: COX2 expression and nodal status 
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 When COX2 expression was compared with the clinical stage of the 
disease, it was noted that COX2 expression was more in tumors of higher 
clinical stage. In lower stages of tumor like stage IA and stage IB, none of the 
tumors showed COX2 positivity. In higher stages of tumor, COX2 expression 
was also noted to be more. However, this correlation was not found to be 
statistically significant.  
 
Table 20: COX2 expression and clinical stage 
 
Clinical stage 
COX2 expression  
Total 
Negative Positive 
IA 1 0 1 
IB 7 0 7 
IIA 4 3 7 
IIB 6 2 8 
IIIA 3 5 8 
IIIB 7 9 16 
IV 3 0 3 
Total 31 19 50 
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When COX2 expression was correlated with the histopathological 
subtype of carcinoma, it was seen that higher COX2 expression was present in 
squamous cell carcinoma (42%), than in adenocarcinoma (25%).  
Table 21: COX2 expression & histological subtypes of carcinoma 
 
 
Histological subtypes 
COX2 expression  
 
Total Negative Positive 
 
Well differentiated SCC 
2 2 4 
 
Moderately  differentiated SCC
15 6 21 
 
Poorly differentiated SCC 
6 8 14 
 
Well differentiated ADC 
3 1 4 
 
Moderately differentiated ADC
1 1 2 
 
Poorly  differentiated ADC 
2 0 2 
 
Adenosquamous carcinoma 
1 0 1 
 
Undifferentiated carcinoma 
1 0 1 
 
Clear cell carcinoma 
0 1 1 
Total 31 19 50 
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DISCUSSION 
 Cervical carcinoma ranks fourth among the leading causes of cancer 
worldwide, after carcinoma of breast, colorectal carcinoma and lung 
carcinoma. In developing countries like India, cervical carcinoma accounts for 
the second most common cancer occurring in women and also the second 
leading cancer killer next only to carcinoma breast. According to WHO (2005), 
more than 5 lakh new cases of carcinoma of cervix are diagnosed every year, of 
which more than 90% are in developing countries. In India, around 50000 new 
cases are diagnosed every year. 
 Cervical carcinoma is unique in that it is one of the most preventable as 
well as treatable cancer, provided it is detected early in the course. Several 
screening procedures have been introduced for the early detection of cancer 
cervix, which includes pap smear, HPV screening, colposcopy, VIA, VILI, 
cervix biopsy.  
 The incidence of squamous cell carcinoma of cervix is decreasing for 
the past two decades. But the incidence of adenocarcinoma is seen to be 
increasing. According to the National Cancer Registry Programme (ICMR), 
most of the urban population in India are showing a statistically significant 
reduction in the incidence of carcinoma of cervix [101]. But since more than 
70% of Indian population still resides in the rural areas, cancer of cervix still 
remain to be a leading cause of cancer related morbidity and mortality in Indian 
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women. According to hospital based cancer registries (HBCR), carcinoma of 
cervix is the most common cancer in women in Chennai and Bangalore[101]. 
 Infection with high risk variants of HPV is considered to be the most 
important etiological factor for the development of carcinoma of cervix. Others 
include early age of first sexual activity, multiple sexual partners, low 
socioeconomic status, poor personal hygiene, smoking, immunosuppression, 
along with other environmental and genetic factors. 
 The various prognostic factors of carcinoma of cervix include age, stage, 
tumor size, depth of invasion, lymphovascular invasion, parametrial 
involvement, vaginal involvement and nodal status. In this study, the role of 
COX2 expression as a prognostic marker for carcinoma of cervix is being 
evaluated by comparing COX2 expression with other established poor 
prognostic factors. 
 Kosary et al. analysed relative survival rates in 17,119 cases of cervical 
cancer and showed that FIGO stage, histological grade, age at diagnosis and 
lymph node status are all independent prognostic factors[102]. 
 Geetha et al. by a hospital based retrospective study[103] and Viladiu et 
al.[104]found that clinical stage is the only independent prognostic factor for 
carcinoma of cervix. 
 According to Baalbergen et al. FIGO stage, grade and lymph node 
metastasis are the most important prognostic factors[105]. 
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 COX2 (cyclooxygenase 2) is a key enzyme in prostaglandin 
metabolism. It is an inducible enzyme unlike COX1 which is constitutively 
present in all cells. COX2 enzyme has been studied extensively and its 
concentration has been found to be increased in many tumors including 
malignancies of oesophagus, colon, pancreas, cervix etc.  
It is noted that COX2 expression is involved in both early and late 
stages of carcinogenesis [106]. Altered COX2 expression is noted in several  
malignanttumors because COX-2 is present independently in cells during the 
early stages of cell differentiation or replication[107, 108]. Bandyopadhyay et 
al.[109] has shown that COX2 is expressed more in invasive malignancies than 
in situ carcinoma of cervix. He also emphasised the need for further studies to 
determine the role of selective COX2 inhibitors in management of cervical 
carcinoma.  
 
EPIDEMIOLOGY OF CERVICAL CARCINOMA IN OUR 
DEPARTMENT (JANUARY 2014 – DECEMBER 2014) 
 In the study period of 12 months from January 2014 to December 2014 
a total of 511 cervix carcinoma cases were received in the Department of 
Pathology, Institute of Obstetrics and Gynaecology, Egmore, Chennai. Of 
these, 502 were cervix biopsies and 9 were hysterectomies. The statistics for 
the year 2014 are as follows: 
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• Among the 502 small biopsies, 466 were squamous cell carcinoma, 27 were 
adenocarcinoma, 5 were undifferentiated carcinoma, and one each of clear cell 
carcinoma of cervix, malignant mixed mulleriantumor of cervix, poorly 
differentiated carcinoma and adenosquamous carcinoma. 
• Among the 9 hysterectomies, 3 were squamous cell carcinoma of moderately 
differentiated grade, 3 were squamous cell carcinoma - poorly differentiated 
grade and 3 were adenocarcinoma well differentiated grade. 
• The most common type of carcinoma of cervix was squamous cell carcinoma 
(92.36%), followed by adenocarcinoma (5.87%) 
 
THE CURRENT STUDY GROUP 
 This was a retrospective study involving 50 cases conducted at the 
Department of Pathology, Institute of Obstetrics and Gynaecology, Egmore, 
Chennai. Since only 9 cases of Werthims hysterectomy cases were received 
during this period that satisfied the inclusion criteria, all of these were included 
in our study. Remaining 41 cases were small biopsies which were selected 
randomly.   
In our study group, the age of patients with carcinoma of cervix range 
from 40 – 80 years with mean age of 55.62 years. Maximum number of 
patients (36%) were of the age group  40-50years, closely followed by 51- 60 
years age group (34%). No patients were present of age <35 years or >80 years. 
This is in accordance to multivariate analysis on Prognostic factors for 
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squamous cell cervical cancer by Annika Lindström were the mean age was 
56.8years. Study by Geetha et al. also showed that occurrence of carcinoma of 
cervix is low in women of age <30 years and >70 years[103]. 
In our study group, carcinoma of cervix was found most commonly in 
post menopausal females (78%). The incidence in menstruating females were 
22%. 
Of the 50 cases included in our study, most common stage was stage 
IIIB which comprised 16 cases (32%) followed by stage IIB and stage IIIA 
each of which comprising 8 cases (16%) each. 
The incidence of parametrial involvement in or study was 64%, vaginal 
involvement was 76% and clinically identifiable lymph node enlargement was 
86%.  
In the study group of 50 cases, the most common histological subtype of 
carcinoma was squamous cell carcinoma, followed by adenocarcinoma. This 
was similar to the study by Kosary et al and Ferrandina et al[110] 
On comparing the age of the patients with COX2 expression, it was 
found that the expression of COX2 was lesser in younger females i.e 40-50 
years age group (33.33%) when compared to females of older age group i.e age 
more than 50 years (40. 26%). So COX2 expression pattern in our study was 
correlating with age of the patient, which is an established poor prognostic 
factor. Ferrandina et al showed a higher incidence of COX2 positivity in 
older patients when compared to younger females. Miaoling et al[85] also 
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showed a similar incidence. But study by Manchana et al failed to 
demonstrate a significant correlation between age of the patient and COX2 
expression[111].  
On comparing menstrual status and stage of the disease, it was noted 
that there was a statistically significant correlation between these two with a p 
value of 0.004. This indicated that younger age group females presented in the 
early stages of disease when compared to older age group females. 
When the size of the tumors were compared with COX2 expression, it 
was noted that smaller tumors showed less COX2 expression whereas it was 
significantly higher for larger tumors. This was found to be statistically 
significant with a p value of 0.007. Such a statistically significant correlation 
between tumor size and COX2 expression was also noted in studies by Kim et 
al[112] , Miaoling et al and Ferrandina et al But a statistically significant 
correlation was not observed in studies by Khunamornpong et 
al[113]andManchana et al. 
In our study, no correlation was noted on comparing COX2 expression 
with parametrial involvement. Positive association between COX2 expression 
and parametrial invasion has been noted in invasive cervical carcinoma stage 
IB by Ryu et al[80]Manchana et al, Ferrandina et al and Miaoling et alalso 
demonstrated statistically significant correlation between COX2 expression and 
paramertial involvement by the tumor. No association with pararmetrial 
invasion was noted by Kim et al[114]. and Khunamornpong et al. 
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When COX2 expression was correlated with vaginal involvement by the 
tumor, it was noted that tumors with vaginal involvement were showing 
increased COX2 expression than those in which vagina was free of tumor. 
Vaginal involvement by the tumor has not been studied specifically in any of 
the studies.  
In our study group, COX2 expression was found to be higher in patients 
with lymph node enlargement detected clinically. This was found to be 
statistically significant with a p value of 0.026. This is supported by studies by 
Miaoling et alManchana et al,  Khunamornpong et alandRyu et alwho also 
demonstrated statistically significant correlation between these two in their 
studies. No association between COX2 expression and clinically enlarged 
lymph nodes were noted by Ferrandina et aland Kim et al.  
Statistically significant correlation between presence of lymphovascular 
emboli and positive COX2 expression has been described in studies by 
Bandyopadhyay et al,Ryu et al, Kim et al and Khunamornpong et al. In our 
present study no such comparison could be done because 82% of cases in our 
study were cervix  biopsies. 
In the present study, COX2 expression was associated with higher 
clinical (FIGO) stage of the disease. But this association was not found to be 
statistically significant. Statistically significant association between COX2 
expression and FIGO stage were noted in studies by Miaoling et 
alandFerrandina et al. Other studies like those by Khunamornpong et al 
showed no correlation between these two factors. 
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When COX2 expression was correlated with the histopathological 
subtype of carcinoma, it was seen that higher COX2 expression was present in 
squamous cell carcinoma (42%), than in adenocarcinoma (25%). This is not in 
concordance with studies by Ferrandina et al,Yong Bae Kim et 
al[114]Manchana et aland Bandyopadhyay et al where higher COX2 
expression was noted in adenocarcinoma than in squamous cell carcinoma.  
On comparing COX2 expression with histological grade higher 
expression was seen in poorly differentiated SCC than in well and moderately 
differentiated grades. But this was not statistically significant.  No such 
associations were noted in adenocarcinoma grades. This result is in 
concordance with studies by Ferrandina et al,  Dursun et al[115],  Lee JS et 
al[116] and Bandyopadhyay et al.  
According to our study, COX2 expression correlated significantly with 
size of the tumor, clinically detected enlarged lymph nodes and increased age 
of the patients, each of which are independent prognostic factors of carcinoma 
of cervix. Hence it can be concluded that positive COX2 expression can be 
considered as a poor prognostic marker and can aid in determining the 
treatment options for these patients. 
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SUMMARY 
• In the study period of 12 months from January 2014 to December 2014 a total 
of 511 cervix carcinoma cases were received in the Department of Pathology, 
Institute of Obstetrics and Gynaecology, Egmore, Chennai. 
• Of these, hysterectomy cases were 9(1.76%) and small biopsies were 502 
(98.24%). 
• In the present study, the age of patients with carcinoma of cervix range from 40 
– 80 years with mean age of 55.62 years. Maximum number of patients (36%) 
were of the age group  40-50years, closely followed by 51- 60 years age group 
(34%). 
• In our study group, carcinoma of cervix was found most commonly in post 
menopausal females (78%). The incidence in menstruating females were 22%. 
• Of the 50 cases included in our study, most common stage was stage IIIB 
which comprised 16 cases (32%) followed by stage IIB and stage IIIA each of 
which comprising 8 cases (16%) each. 
• The size of tumor ranged from less than 0.5 cm to 8cm. Most of the tumors 
(80%) were more than 4 cm in size.  
• 64% of tumors had parametrial involvement, 24% upto the lateral pelvic wall. 
36% of cases had no parametrial involvement. 
• Vaginal involvement was present in 76% of cases. 
• 86% of the cases under study had enlarged lymph nodes which were detected 
radiologically, whereas in 14% of cases nodes were not detected. 
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• In our study group of 50 cases squamous cell carcinoma was the most common 
histological type. Among squamous cell carcinomas, most common was 
moderately differentiated grade (54%), followed by poorly differentiated grade 
(36%). 
• When the menstrual status and stage of the disease were compared, it was 
noted that menstruating females presented in early stages of the disease, 
whereas postmenopausal females presented in advanced stages of disease. This 
correlation was statistically found to be significant with a p value of 0.004. 
• When age of the patients was correlated with COX2 expression, it was found 
that the expression of COX2 was lesser in younger females i.e 40-50 years age 
group (33.33%) when compared to females of older age group i.e age more 
than 50 years (40. 26%). 
• In our study, it was noted that smaller tumors showed less COX2 expression 
whereas it was significantly higher for larger tumors. This was found to be 
statistically significant with a p value of 0.007. 
• When COX2 expression was compared with the parametrial involvement of the 
tumor no positive correlation was noted. 
• When COX2 expression was correlated with vaginal involvement by the tumor, 
it was noted that tumors with vaginal involvement were showing increased 
COX2 expression than those in which vagina was free of tumor. 
• On comparing the COX2 expression with nodal status of the patients, it was 
noted that among cases with enlarged nodes, 44.2% had positive COX2 
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expression. This was found to be statistically significant with a p value of 
0.026. 
• On comparing COX2 expression with clinical stage of the disease, it was noted 
that COX2 expression was more in tumors of higher clinical stage. 
• In our study it was seen that higher COX2 expression was present in squamous 
cell carcinoma (42%), than in adenocarcinoma (25%).  
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CONCLUSION 
• Cervical carcinoma ranks fourth among the leading causes of cancer 
worldwide. In India, it is the second leading cancer killer next only to 
carcinoma breast. 
• Several studies, including our present study have pointed towards the 
possibility of considering COX2 as a poor prognostic marker for cervix 
carcinoma. 
• Immunohistochemistry is an easier and effective method for identification of 
prognostic markers early in the course of disease so that patients can be 
categorised and appropriate treatment protocol decided. 
• As surgical pathologists, our role does not end merely in diagnosing a 
malignancy or classifying it, but it is our responsibility to help the clinician in 
deciding the appropriate treatment for patients. 
• In this era of targeted therapy, more studies should be conducted to detect 
possible theranostic markers so that targeted therapy can be implemented 
effectively against this common killer disease. 
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ANNEXURE I 
 
   
ANNEXURE II 
PROFORMA 
 
Name    :  
Age     : 
IP Number   : 
Biopsy No   : 
Presenting symptoms :   post coital bleeding/post-menopausal  
 bleeding 
Menstrual status  :   menstruating/ post-menopausal 
Speculum Examination :   growth present/ absent 
Per Vaginal Examination : parametrial& vaginal invasion 
Per Rectal Examnation :   rectal invasion 
Ultrasound findings : 
CT findings   : 
Cystoscopy findings :   bladder mucosal involvement 
Clinical diagnosis  : 
Type of specimen  :   cervix biopsy/ hysterectomy 
Gross    :   growth present/ absent 
Microscopy  : Histological diagnosis according to WHO  
  classification 
IHC (COX2 expression) :   negative/ mild/ moderate/ strong  
     positivity 
ANNEXURE III 
2009 modification of FIGO staging of carcinoma of cervix 
Stage      Definition 
I Cervical carcinoma confined to uterus (extension to the corpus 
should be disregarded) 
IA  Invasive carcinoma diagnosed only by microscopy; all 
macroscopically visible lesions, even with superficial invasion, 
are stage IB 
IA1  Stromal invasion no greater than 3.0 mm in depth and 7.0 mm or 
less in horizontal spread 
IA2 Stromal invasion more than 3.0 mm and not more than 5.0 mm 
with a horizontal spread of 7.0 mm orless 
IB Clinically visible lesion confined to the cervix or microscopic 
lesion greater than IA2 
IB1  Clinically visible lesion 4.0 cm or less in greatest dimension 
IB2  Clinically visible lesion more than 4.0 cm in greatest dimension 
II Tumor invades beyond the uterus but not to pelvic wall or to 
lower third of the vagina 
IIA  Without parametrial invasion 
IIA1   Clinically visible lesion 4.0 cm in greatest dimension 
IIA2   Clinically visible lesion >4 cm in greatest dimension 
IIB   With parametrial invasion 
III  Tumor extends to the pelvic wall and/or involves lower third of 
vagina and/or causes hydronephrosis or nonfunctioning kidney 
IIIA  Tumor involves lower third of vagina with no extension to pelvic 
wall 
IIIB  Tumor extends to pelvic wall and/or causes hydronephrosis or 
non-functioning kidney 
IV  The carcinoma has extended beyond the true pelvis or has 
involved (biopsy proven) the mucosa of the bladder or rectum.  
IVA   Spread of the growth to adjacent organs 
IVB   Spread to distant organs 
ANNEXURE IV 
MODIFIED WHO CLASSIFICATION OF CERVIX CARCINOMA 
• Squamous cell carcinoma 
o Microinvasive (early invasive) squamous cell carcinoma 
o Invasive squamous cell carcinoma 
 Keratinizing 
 Nonkeratinizing 
 Basaloid 
 Verrucous 
 Warty 
 Papillary 
 Squamotransitional 
 Lymphoepithelioma-like carcinoma 
• Adenocarcinoma 
o Usual type adenocarcinoma 
o Mucinous adenocarcinoma 
 Endocervical type 
 Intestinal type 
 Signet-ring type 
o Minimal deviation 
o Villoglandular 
o Endometrioid adenocarcinoma 
o Clear cell adenocarcinoma 
o Serous adenocarcinoma 
o Mesonephric adenocarcinoma 
• Other epithelial tumors 
o Adenosquamous carcinoma 
 Glassy cell variant 
o Adenoid cystic carcinoma 
o Adenoid basal carcinoma 
o Neuroendocrine tumors 
 Carcinoid 
 Atypical carcinoid 
 Small cell carcinoma 
 Large cell neuroendocrine carcinoma 
o Undifferentiated carcinoma 
ANNEXURE V 
IMMUNOHISTOCHEMISTRY PROCEDURE 
1. 4μ thick sections were cut from formalin fixed paraffin embedded tissue  
samples and transferred to gelatin-chrome alum coated slides. 
2. The slides were incubated at 58ºC for overnight. 
3. The sections were deparaffinized in xylene for 15 minutes x 2 changes. 
4. The sections were dehydrated with absolute alcohol for 5 minutes x 2 
changes. 
5. The sections were washed in tap water for 10 minutes. 
6. The slides were then immersed in distilled water for 5 minutes. 
7. Heat  induced  antigen  retrieval  was  done  with  microwave  oven  in  
appropriate temperature with appropriate buffer for 20 to 25 minutes. 
8. The slides were then cooled to room temperature and washed in running tap 
water for 5 minutes. 
9. The slides were then rinsed in distilled water for 5 minutes. 
10. Wash with appropriate wash buffer (phosphate buffer) for 5 minutes x 2 
changes. 
11. Apply peroxidase block over the sections for 10 minutes. 
12. Wash the slides in phosphate buffer for 5 minutes x 2 changes. 
13. Cover the sections with power block for 15 minutes. 
14. The sections were drained (without washing)  and  appropriate  primary  
antibody was applied over the sections and incubated for 45 minutes. 
15. The slides were washed in phosphate buffer for 5 minutes x 2 changes. 
16. The slides were covered with Super Enhancer for 30 minutes. 
17. The slides were washed in phosphate buffer for 5 minutes x 2 changes. 
18. The slides were covered with SS Label for 30 minutes. 
19. Wash in phosphate buffer for 5 minutes x 2 changes. 
20. DAB  substrate  was  prepared  by  diluting  1  drop  of  DAB  chromogen  
to  1ml  of DAB buffer. 
21. DAB substrate solution was applied on the sections for 8 minutes. 
22. Wash with phosphate buffer solution for 5 minutes x 2 changes. 
23. The slides are washed well in running tap water for 5 minutes. 
24. The sections were counterstained with Hematoxylin stain for 2 seconds (1 
dip). 
25. The slides are washed in running tap water for 3 minutes. 
26. The slides are air dried, cleared with xylene and mounted with DPX. 
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MASTER CHART 
serial 
no. 
biopsy 
no 
age menstrual 
status 
stage tumor 
size 
parametrialinvolv vagina 
involv 
nodal 
status 
type of 
specimen 
HPE 
diagnosis 
COX 2 
1 3 50 PMP 4 >4 2 2 P CERVIX BIOPSY 2 1+ 
2 36 60 PMP 7 >4 3 3 P CERVIX BIOPSY 6 1+ 
3 68 50 PMP 6 >4 2 2 P CERVIX BIOPSY 2 N 
4 156 65 PMP 3 0.5 - 4 1 2 P CERVIX BIOPSY 5 N 
5 189 60 PMP 6 >4 3 3 P CERVIX BIOPSY 4 3+ 
6 198 42 Menstruating 5 >4 1 1 P CERVIX BIOPSY 2 3+ 
7 269 55 PMP 6 >4 3 2 P CERVIX BIOPSY 3 2+ 
8 272 65 PMP 4 >4 2 2 P CERVIX BIOPSY 3 1+ 
9 431 57 PMP 6 >4 2 2 P CERVIX BIOPSY 2 N 
10 454 55 PMP 7 >4 2 2 P Hysterectomy 3 N 
11 461 40 Menstruating 6 >4 2 2 P CERVIX BIOPSY 2 2+ 
12 505 50 PMP 5 >4 1 3 P CERVIX BIOPSY 3 1+ 
13 538 48 PMP 6 >4 3 3 P CERVIX BIOPSY 2 N 
14 582 65 PMP 5 >4 2 3 P CERVIX BIOPSY 6 N 
15 601 52 PMP 4 >4 2 2 P CERVIX BIOPSY 3 N 
16 602 75 PMP 3 >4 1 2 P CERVIX BIOPSY 3 2+ 
17 644 48 Menstruating 6 >4 2 3 P CERVIX BIOPSY 2 2+ 
18 675 65 PMP 6 >4 3 3 P CERVIX BIOPSY 2 N 
19 848 42 Menstruating 4 >4 2 1 A CERVIX BIOPSY 2 1+ 
20 851 65 PMP 4 >4 2 1 P CERVIX BIOPSY 2 1+ 
21 939 55 PMP 6 >4 2 2 P CERVIX BIOPSY 2 2+ 
22 995 58 PMP 3 0.5 - 4 1 2 P CERVIX BIOPSY 1 1+ 
23 1009 62 PMP 4 >4 2 2 P CERVIX BIOPSY 7 1+ 
24 1041 55 PMP 6 >4 3 3 P CERVIX BIOPSY 2 N 
25 1072 60 PMP 5 >4 3 3 P CERVIX BIOPSY 1 2+ 
26 1179 50 PMP 5 >4 2 3 P CERVIX BIOPSY 2 2+ 
27 1532 40 Menstruating 2 0.5 - 4 1 1 P Hysterectomy 2 N 
28 1598 40 Menstruating 1 <0.5 1 1 A Hysterectomy 3 1+ 
29 1685 65 PMP 6 >4 3 2 P CERVIX BIOPSY 1 1+ 
30 1841 60 PMP 3 >4 1 2 P CERVIX BIOPSY 3 3+ 
31 1857 50 PMP 2 >4 1 1 A Hysterectomy 4 N 
32 1889 56 PMP 4 >4 1 2 P Hysterectomy 3 2+ 
33 1952 53 PMP 6 >4 3 2 P CERVIX BIOPSY 3 2+ 
34 1953 45 Menstruating 3 >4 1 2 P CERVIX BIOPSY 2 1+ 
35 2021 41 Menstruating 2 0.5 - 4 1 1 A CERVIX BIOPSY 2 N 
36 2024 60 PMP 5 >4 2 2 P CERVIX BIOPSY 2 1+ 
37 2034 65 PMP 5 >4 2 3 P CERVIX BIOPSY 1 2+ 
38 2134 60 PMP 7 >4 2 3 P CERVIX BIOPSY 2 1+ 
39 2135 57 PMP 2 0.5 - 4 1 1 P CERVIX BIOPSY 2 N 
40 2220 62 PMP 5 >4 2 3 P CERVIX BIOPSY 3 3+ 
41 2242 67 PMP 6 >4 3 3 P CERVIX BIOPSY 3 2+ 
42 2309 40 Menstruating 2 o.5 - 4 1 1 A Hysterectomy 4 1+ 
43 2676 49 PMP 4 >4 2 1 P CERVIX BIOPSY 9 2+ 
44 2743 65 PMP 6 >4 2 2 P CERVIX BIOPSY 2 2+ 
45 2784 65 PMP 6 >4 3 2 P CERVIX BIOPSY 8 1+ 
46 2874 80 PMP 3 0.5 - 4 1 2 P Hysterectomy 2 N 
47 2980 62 PMP 6 >4 3 2 P CERVIX BIOPSY 3 2+ 
48 2987 45 Menstruating 3 >4 1 2 P CERVIX BIOPSY 5 2+ 
49 3067 60 PMP 2 0.5 - 4 1 1 A Hysterectomy 3 N 
50 3105 45 Menstruating 2 0.5 - 4 1 1 A Hysterectomy 4 N 
 
KEY TO MASTER CHART 
 
 
PMP :    Post-menopausal 
Stage  
          1 :    IA 
          2 :    IB 
          3 :    IIA 
          4 :    IIIA 
          5 :    IIIB 
          6 :    IIIB 
          7 :    IV 
Parametrial involvement  
          1 :    Parametrium is free 
          2 :    Parametrialinvolved, not upto pelvic wall 
          3 :    Parametrialinvolved uptopelvic wall 
Vaginal involvement  
          1 :    Vagina is free 
          2 :    Upper 1/3rd of vagina is involved 
          3 :    Lower 2/3rd of vagina is involved 
nodal status  
         P :    Present  
         A :    Absent 
HPE diagnosis  
          1 :    Well differentiated SCC 
          2 :    Moderately differentiated SCC 
          3 :    Poorly differentiated SCC 
          4 :    Well differentiated ADC 
          5 :    Moderately differentiated ADC 
          6 :    Poorly differentiated ADC 
          7 :    Adenosquamous carcinoma 
          8  :    Undifferentiated carcinoma 
          9 :    Clear cell carcinoma 
COX2   
         N :    Negative 
        1+ :    <10% tumor cells positive 
        2+ :    10-50% tumor cells positive 
        3+ :    >50% tumor cells positive 
 
